As TLR4 pathway is also activated in MM mesenchymal stromal cells (MSCs) driving their commitment toward a pro-inflammatory and pro-tumor behavior (145), TLR4 inhibition could be an adjuvant therapy to interrupt the self-reinforcing stromal changes in MM microenvironment. Here, TLR4 is linked to neoplasm.